The Vitamin D Test That Became an Annual Ritual

The Claim

A blood test can feel like preventive medicine made visible: one tube, one number, one tidy little arrow pointing up or down. But a measurable number is not automatically a useful screening programme.

For community-dwelling, nonpregnant adults without symptoms or a condition that changes vitamin D management, routine annual 25-hydroxyvitamin D testing has not been shown to prevent fractures, cancer, cardiovascular disease or death. The US Preventive Services Task Force found the evidence insufficient because no completed studies directly tested the benefits and harms of screening asymptomatic adults. [1]

Why This Became Normal

Vitamin D is biologically important. Severe deficiency matters. The assay is easy to order. Low-looking results are common, especially when laboratories, guidelines and clinicians use different thresholds.

That combination is irresistible. The test moved from targeted diagnosis to annual ritual, a sort of serum weather report. The USPSTF noted that Medicare vitamin D testing rose more than eighty-fold from 2000 to 2010. [1] A surge in testing is not proof of harm, but it is certainly not proof of benefit.

What The Best Guidance Says

The 2024 Endocrine Society guideline suggests against routine 25-hydroxyvitamin D testing in healthy adults, including generally healthy people with obesity and darker complexion, because trial evidence has not established outcome-specific blood-level thresholds that should trigger treatment. [2]

The USPSTF reaches the problem from a different direction and still lands in the same awkward waiting room: evidence is insufficient to recommend for or against population screening in asymptomatic adults. “Insufficient” does not mean the test never helps. It means the programme has not earned a blanket promise.

What The Trials Can And Cannot Tell Us

Screening and supplementation are not the same intervention. Still, large trials help test the assumption that finding more modestly low levels and treating broadly must improve major outcomes.

In VITAL, 25,871 US adults were randomly assigned vitamin D3 at 2,000 IU daily or placebo within a factorial trial. Over a median 5.3 years, vitamin D did not significantly reduce invasive cancer or major cardiovascular events in generally healthy adults not selected for deficiency. [3]

A prespecified VITAL fracture analysis confirmed 1,991 incident fractures in 1,551 participants. Vitamin D did not significantly reduce total, nonvertebral or hip fractures, including among people with lower baseline levels. [4] These trials do not prove that testing is useless in every patient. They do make the “test everyone, then supplement everyone” story much less grand than its brochure.

The Strongest Objection

Some clinicians argue that screening identifies people with unexpectedly severe deficiency before bone or muscle consequences appear. That is plausible, and a small high-risk subgroup may benefit from being found.

The trouble is the denominator. A screening programme applies the test to many healthy people, not merely the few with a strong reason to suspect disease. To justify that programme, we need evidence that the full chain—test, threshold, treatment and follow-up—improves outcomes more than targeted clinical assessment. We do not yet have it.

The Exceptions

This argument is not about people with hypocalcaemia, osteomalacia, osteoporosis or fragility fracture; chronic kidney or liver disease; malabsorption or bariatric surgery; symptoms suggesting deficiency; medications that alter vitamin D metabolism; or another clinical reason in which the result will change management. Pregnancy, frailty, institutional living and specialist bone care may also require a different decision.

Nor is it a licence to stop prescribed vitamin D or calcium. A test can be sensible when the pre-test question is sensible. The problem is ordering the answer before anyone has asked a question.

What We Do About It

Before ordering the test, write down the decision it could change. If the result is low, what will happen? If it is normal, what will stop? If neither answer changes care, the tube is doing theatre, not medicine.

For generally healthy adults, focus first on dietary adequacy, safe physical activity, fall prevention, smoking cessation and management of genuine bone-health risks. Avoid high-dose supplementation without a clear indication: vitamin D toxicity can cause hypercalcaemia, kidney injury and other harms. [5]

What Would Change The Verdict

A pragmatic randomized trial of routine screening versus targeted testing, using prespecified thresholds and treatment, could change this conclusion if it showed fewer fractures, falls or other patient-important outcomes without offsetting harms and cost. Better agreement on assay thresholds would help too.

Until then, measuring sunshine in everybody’s blood is a surprisingly expensive way to discover that weather is complicated.

Sources and receipts

1. [1] US Preventive Services Task Force. Vitamin D Deficiency in Adults: Screening, final recommendation statement, April 13, 2021. — Source cited in the reviewed article
2. [2] Endocrine Society. Vitamin D for the Prevention of Disease: Clinical Practice Guideline, June 2024. — Source cited in the reviewed article
3. [3] Manson JE et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine. 2019;380:33-44. DOI 10.1056/NEJMoa1809944. — Source cited in the reviewed article
4. [4] LeBoff MS et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. New England Journal of Medicine. 2022;387:299-309. DOI 10.1056/NEJMoa2202106. — Source cited in the reviewed article
5. [5] National Institutes of Health Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals, adverse effects and upper limits. — Source cited in the reviewed article
6. [6] Pittas AG et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine. 2019;381:520-530. DOI 10.1056/NEJMoa1900906. — Source cited in the reviewed article